1. Home
  2. DSGN vs FC Comparison

DSGN vs FC Comparison

Compare DSGN & FC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • FC
  • Stock Information
  • Founded
  • DSGN 2017
  • FC 1983
  • Country
  • DSGN United States
  • FC United States
  • Employees
  • DSGN N/A
  • FC N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • FC Other Consumer Services
  • Sector
  • DSGN Health Care
  • FC Consumer Discretionary
  • Exchange
  • DSGN Nasdaq
  • FC Nasdaq
  • Market Cap
  • DSGN 208.9M
  • FC 224.0M
  • IPO Year
  • DSGN 2021
  • FC 1992
  • Fundamental
  • Price
  • DSGN $5.74
  • FC $17.68
  • Analyst Decision
  • DSGN
  • FC Strong Buy
  • Analyst Count
  • DSGN 0
  • FC 2
  • Target Price
  • DSGN N/A
  • FC $27.00
  • AVG Volume (30 Days)
  • DSGN 201.9K
  • FC 102.3K
  • Earning Date
  • DSGN 11-06-2025
  • FC 11-05-2025
  • Dividend Yield
  • DSGN N/A
  • FC N/A
  • EPS Growth
  • DSGN N/A
  • FC N/A
  • EPS
  • DSGN N/A
  • FC 0.81
  • Revenue
  • DSGN N/A
  • FC $279,943,000.00
  • Revenue This Year
  • DSGN N/A
  • FC N/A
  • Revenue Next Year
  • DSGN N/A
  • FC $1.23
  • P/E Ratio
  • DSGN N/A
  • FC $21.71
  • Revenue Growth
  • DSGN N/A
  • FC N/A
  • 52 Week Low
  • DSGN $2.60
  • FC $17.06
  • 52 Week High
  • DSGN $7.77
  • FC $44.16
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 43.44
  • FC 40.52
  • Support Level
  • DSGN $6.01
  • FC $17.15
  • Resistance Level
  • DSGN $7.21
  • FC $18.08
  • Average True Range (ATR)
  • DSGN 0.62
  • FC 0.64
  • MACD
  • DSGN -0.12
  • FC -0.10
  • Stochastic Oscillator
  • DSGN 3.65
  • FC 25.00

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.

Share on Social Networks: